Compare AT&T Inc. (T) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AT&T Inc. vs TransMedics Group Inc — how do they compare? AT&T Inc. trades at $25.2 (market cap $175.42B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: AT&T Inc. is far larger — about 57.3× TransMedics Group Inc's market cap, and AT&T Inc. pays a 4.34% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| T | TMDX | |
|---|---|---|
Market Cap | $175.42B | $3.06B |
Sector | Media | Technology |
52-Week High | $29.62 | $150.42 |
52-Week Low | $20.49 | $61.99 |
Enterprise Value | $320.74B | $3.46B |
Dividend Yield | 4.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $25.61, down slightly by 0.21% on the day. The stock exhibits a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company reported robust earnings, beating estimates in recent quarters, with a net income margin of 16.94% and attractive valuation ratios like a P/E of 8.45. Recent news highlights strategic focus on fiber and wireless growth, including a partnership with Amazon for satellite broadband.
The outlook for AT&T is positive, supported by consistent earnings beats, a solid dividend, and strategic initiatives in fiber and 5G. Key risks include high debt levels and intense competition. Analysts maintain a consensus buy rating with a $27.69 price target, suggesting potential upside from current levels.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
